Format

Send to

Choose Destination
Curr Gene Ther. 2017;17(4):275-285. doi: 10.2174/1566523217666171121164615.

CRISPR/Cas9 Editing to Facilitate and Expand Drug Discovery.

Author information

1
Department of Biochemistry, McGill University, Montreal, QC, H3G 1Y6, Canada.
2
Rosalind and Morris Goodman Cancer Research Center, McGill University, Montreal, QC, H3G 1Y6, Canada.
3
Department of Oncology, McGill University, Montreal, QC, H3G 1Y6, Canada.

Abstract

INTRODUCTION:

The ability of most laboratories to easily access CRISPR/Cas9 engineering tools has caused a revolution in biology. One of the areas that will continue to be impacted by genome editing is the drug discovery process.

OBJECTIVE:

CRISPR/Cas9 will not only serve to accelerate the drug discovery pipeline, but also streamline line it by identifying high-value targets, facilitating the validation of drug: target interactions and mechanisms of action, and stimulating the development of phenotype-based high throughput screens as alternatives to target-based assays.

CONCLUSION:

We review the literature and hurdles that have been overcome to develop the current generation of tools being used to enrich the drug discovery paradigm.

KEYWORDS:

Base editing; CRISPR/Cas9; Drug discovery; Druggable genome; RNA; Target: drug interaction validation

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center